Ireland-based medical device company Covidien has launched its EverFlex self-expanding peripheral stent with Entrust delivery system in Australia and New Zealand.
Covidien claims that the Entrust delivery system enables physicians to consistently place stents with accuracy while providing the ease of a one-handed device.
The Entrust delivery system deploys the EverFlex stent that is used to re-open narrowed regions of the superficial femoral and proximal popliteal arteries, which supply blood to the legs. Narrowing of these arteries is associated with a condition known as peripheral arterial disease (PAD).
Three-year data from the DURABILITY II study showed that the EverFlex stent is able to sustain patency and durability even in long, complex lesions.
The Entrust Delivery System allows physicians to deploy all sizes, up to 150mm lengths, of the Covidien EverFlex stent on a low 5 F profile with preserved radial force.
Epworth Hospital, Richmond, associate professor Michael Denton said that it is impressive to see the existing EverFlex stent now available on an easy to use, low profile, triaxial designed delivery system.
"With a lower profile, the puncture site is smaller, possibly resulting in fewer access site complications and faster ambulatory rates," Denton added.
Covidien Vascular Therapies chief medical officer Mark Turco said that its Entrust delivery system allows for one-handed delivery of the EverFlex stent for treating patients with PAD.
"The design of the system is based on extensive physician feedback and procedural observation, and should allow for better performance during stent deployment," Turco added.